Alecensa (alectinib) is a small molecule pharmaceutical. Alectinib was first approved as Alecensa on 2015-12-11. It is used to treat non-small-cell lung carcinoma in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma. The pharmaceutical is active against ALK tyrosine kinase receptor. In addition, it is known to target hepatocyte growth factor receptor. Alecensa's patent is valid until 2035-04-24 (FDA).
|Indication||non-small-cell lung carcinoma|
|Drug Class||Tyrosine kinase inhibitors|